◆ NeutralENTX
Entera Bio to Participate in the Canaccord Genuity 46th Annual Growth Conference
GlobeNewswire Inc.·
Entera Bio Ltd. (NASDAQ: ENTX), a clinical-stage biopharmaceutical company developing oral peptide therapies, announced that CEO Miranda Toledano will participate in a fireside chat at the Canaccord Genuity 46th Annual Growth Conference on August 12, 2026. The company is advancing its lead candidate EB613 (oral PTH(1-34)) for osteoporosis treatment, which met primary and secondary endpoints in a Phase 2 study, with positive FDA feedback received on planned Phase 3 registrational studies.
Read Full Article at GlobeNewswire Inc. →